P Pharming Group NV
P
Fechado
1.174 -0.25
Visão Geral
Variação de preço das ações
24h
Mín
1.149
Máximo
1.187
Rendimento | -10M -5.1M |
|---|---|
Vendas | -36M 71M |
P/E Médio do Setor | 59.5 50.102 |
EPS | -0.006 |
Margem de lucro | -7.196 |
Funcionários | 407 |
EBITDA | -4.8M -2.1M |
Próximos Ganhos | 30 de jul. de 2026 |
|---|
Capitalização de Mercado | -168M 840M |
|---|---|
Abertura anterior | 1.42 |
Fecho anterior | 1.174 |
Pharming Group NV Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Notícias Relacionadas
Comparação entre Pares
Variação de preço
Pharming Group NV Previsão
Informação Financeira
Custos administrativos e de venda
Custos Operacionais
Lucro antes de imposto
Vendas
Custo das vendas
Lucro bruto sobre vendas
Despesa com juros da dívida
EBITDA
Resultado Operacional
$
Sobre Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
